Remogliflozin etabonate
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.
Product Specifications
CAS Number
442201-24-3
Purity
>98% (HPLC)
Solubility
In Vitro: DMSO : 100 mg/mL (191.35 mM; Ultrasonic)
Smiles
CCOC (=O) OC[C@H]1O[C@@H] (Oc2nn (C (C) C) c (C) c2Cc2ccc (OC (C) C) cc2) [C@H] (O) [C@@H] (O) [C@@H]1O
Molecular Formula
C26H38N2O9
Molecular Weight
522.59
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC041758-500 1x 500 µL
CELA3B / ELA3B (Pancreatic Function Marker) (CELA3B/1758), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
